Vical/Astellas's TransVax first therapeutic CMV vaccine to Phase III
This article was originally published in Scrip
Vical and partner Astellas have become the first firms to take an investigational therapeutic vaccine for cytomegalovirus (CMV) into a Phase III clinical study, moving their candidate TransVax (ASP0113) into a pivotal multinational program in hematopoietic stem cell transplant (HSCT) recipients.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.